Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

Authors: Thomas R. Pieber, Bruce W. Bode, Ann Mertens, Young Min Cho, Erik Christiansen, CHRISTIN L. HERTZ, Signe Olrik Rytter Wallenstein, John B. Buse, Serkan Akın, Nesim Aladağ, Ahmed A. Arif, Louis J. Aronne, S Aronoff, Hayriye Esra Ataoğlu, Sei Hyun Baik, Harold Bays, Patricia Beckett, Dilek Berker, Stefan Bilz, Bruce W. Bode, E Braun, John B. Buse, Luís Henrique Santos Canani, Y M Cho, Choon Hee Chung, Ides M. Colin, Jonathan Condit, John G. Cooper, Bruno Delgado, Donald Eagerton, I N El Ebrashy, Mohamed Hesham Mohamed Fahmy El Hefnawy, Freddy G. Eliaschewitz, MATTHEW FINNERAN, Stefan Fischli, Evelyn Fließer-Görzer, Jeff Geohas, Narendra Godbole, A Golay, SILIVA LAPERTOSA, Jens Gross, Hanne Løvdal Gulseth, F Helland, Hans Olav Høivik, Claire Michael Issa, Eun Seok Kang, Claus Keller, Samir Helmy Assaad Khalil, N H Kim, I J Kim, Leslie J. Klaff, Martin Laimer, Jordan C. Larocque, Samuel Lederman, K-W Lee, W. Reid Litchfield, M B Manning, Ann Mertens, Emily Morawski, Alexander V. Murray, Philip Nicol, Thomas M. O'Connor, Aytekin Oğuz, Sean Wei Xiang Ong, Ali Özdemir, E M Palace, Bryce Palchick, J Pereles-Ortiz, Thomas R. Pieber, Rudolf Prager, Vanessa Preumont, Ernie Riffer, Lucas Rista, Gottfried Rudofsky, RAMAZAN SARI, André Scheen, Bernd Schultes, Ji A Seo, Sara Shelbaya, Kanagaratnam Sivalingam, Christopher Sorli, S Stäuble, Dan Streja, Guy T’Sjoen, Tamer Tetıker, L. Van Gaal, Chris Vercammen, Mark Warren, D. Weinstein, D Weiss, Alexander White, Michael Winnie, Cecilie Wium, Dilek Gogaş Yavuz - The Lancet 2019 cited by 274